In 2017, three groundbreaking immunotherapies for relapsed and/or refractory B-cell acute lymphoblastic leukaemia (ALL) were approved based on impressive outcomes observed in clinical trials. Additional breakthroughs included seminal research into ALL genomics and the importance of adherence to chemotherapy, which will have direct implications for clinical care.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).
Kantarjian, H. M. et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 4, e387–e398 (2017).
Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).
von Stackelberg, A. et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34, 4381–4389 (2016).
Martiinelli, G. et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA) [abstract]. Blood 126, 679 (2015).
Boechner, J. et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): update to the interim analysis. Haematologica 102, S476 (2017).
Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor t-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016).
Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl Med. 9, eaaj2013 (2017).
Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211–1218 (2017).
Landier, W. et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group Study AALL03N1. J. Clin. Oncol. 35, 1730–1736 (2017).
D.T.T. has served on an advisory board for Amgen and received research funding from Novartis. S.P.H. owns stock in Amgen, Merck, and Pfizer, and has received honoraria from Amgen, Erytech, Jazz Pharmaceuticals, and Spectrum Pharmaceuticals, and consulting fees from Novartis.
About this article
Cite this article
Teachey, D., Hunger, S. Immunotherapy for ALL takes the world by storm. Nat Rev Clin Oncol 15, 69–70 (2018). https://doi.org/10.1038/nrclinonc.2017.176
Microrandomized trials for promoting engagement in mobile health data collection: Adolescent/young adult oral chemotherapy adherence as an example
Current Opinion in Systems Biology (2020)
First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
Journal for ImmunoTherapy of Cancer (2020)
Targeting the bone marrow microenvironment: a novel therapeutic strategy for pre-B acute lymphoblastic leukemia
The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
Frontiers in Immunology (2019)
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
The Lancet Oncology (2019)